Cargando…

Sulfidogenic fluidized-bed bioreactor kinetics for co-treatment of hospital wastewater and acid mine drainage

A passive co-treatment of acid mine drainage and hospital wastewater previously demonstrated a promising bioremediation viable approach for both toxic streams. The study of inhibition kinetics and microbial communities is essential to understand better the diverse species and the reaction mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Makhathini, Thobeka Pearl, Mulopo, Jean, Bakare, Babatunde Femi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551841/
https://www.ncbi.nlm.nih.gov/pubmed/34745909
http://dx.doi.org/10.1016/j.btre.2021.e00683
Descripción
Sumario:A passive co-treatment of acid mine drainage and hospital wastewater previously demonstrated a promising bioremediation viable approach for both toxic streams. The study of inhibition kinetics and microbial communities is essential to understand better the diverse species and the reaction mechanisms within the system. The kinetics and microbiology diversity in the sulfidogenic fluidized-bed reactor (at 30 °C) for co-treatment of hospital wastewater and metal-containing acidic water were examined. The alkalinity from organic oxidation raised the pH of the effluent from 2.3 to 6.1–8.2. Michaelis-Menten modeling yielded (K(m) =7.3 mg/l, V(max) = 0.12 mg/l min(−1)) in the batch bioreactor treatment using sulfate-reducing bacteria. For COD oxidation, the dissolved sulfide inhibition constant (K(i)) was 3.6 mg/l, and the K(i) value for H(2)S was 9 mg/l. The dominant species in the treatment process belong to the Proteobacteria group (especially Deltaproteobacteria). The ibuprofen and diclofenac compounds achieved the highest removal rates in the bioreactor of 58.6% and 52.3%, respectively; while, ketoprofen and naproxen of 41.9% and 46.6%, respectively. The findings in COD kinetics, sulfate-reducing bacteria abundance, and selected pharmaceutical concentration reduction provide insight into this co-treatment process's capability.